MCID: PLS006
MIFTS: 51

Plasmodium Vivax Malaria

Categories: Infectious diseases

Aliases & Classifications for Plasmodium Vivax Malaria

MalaCards integrated aliases for Plasmodium Vivax Malaria:

Name: Plasmodium Vivax Malaria 12 15 17 32
Malaria, Vivax 43 71
Malaria by Plasmodium Vivax 12
Vivax Malaria 12
Malaria Vivax 54

Classifications:



External Ids:

Disease Ontology 12 DOID:12978
ICD9CM 34 084.1
MeSH 43 D016780
NCIt 49 C34800
SNOMED-CT 67 27052006
UMLS 71 C0024537

Summaries for Plasmodium Vivax Malaria

Disease Ontology : 12 A malaria that is caused by the protozoan parasite Plasmodium vivax, which induces paroxysms at 48-hour intervals.

MalaCards based summary : Plasmodium Vivax Malaria, also known as malaria, vivax, is related to glucosephosphate dehydrogenase deficiency and acute disseminated encephalomyelitis. An important gene associated with Plasmodium Vivax Malaria is ACKR1 (Atypical Chemokine Receptor 1 (Duffy Blood Group)), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Sulfadoxine and Pyrimethamine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Plasmodium Vivax Malaria

Diseases related to Plasmodium Vivax Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
# Related Disease Score Top Affiliating Genes
1 glucosephosphate dehydrogenase deficiency 31.9 G6PD CYP2D6 ACKR1
2 acute disseminated encephalomyelitis 31.2 IL1B IL10 CD40LG
3 plasmodium ovale malaria 31.1 G6PD CYP2D6
4 syphilis 31.0 TNF IL6 IFNG CD40LG
5 pulmonary edema 31.0 TNF IL1B IL10 ICAM1
6 acute pancreatitis 30.9 TNF IL6 IL1B IL10
7 pancreatitis 30.9 TNF IL6 IL1B IL10
8 acute kidney tubular necrosis 30.9 TNF IL6 CD40LG
9 inclusion body myopathy with early-onset paget disease of bone with or without frontotemporal dementia 3 30.8 DHFR CD40LG ACKR1
10 pancytopenia 30.8 IL6 IFNG DHFR CD40LG
11 anemia, autoimmune hemolytic 30.8 IL2 G6PD CD40LG
12 disseminated intravascular coagulation 30.8 TNF THBD SELE IL6 IL10
13 neurosyphilis 30.8 IL10 CXCL10
14 bronchiolitis obliterans 30.7 TNF IL6 IL10 IFNG
15 glomerulonephritis 30.6 VCAM1 IL1B ICAM1 CD40LG
16 cryptococcosis 30.6 TNF IL10 IFNG
17 lyme disease 30.6 TNF IL6 IL1B CD40LG
18 plasmodium malariae malaria 30.6 DHFR CD40LG
19 intracranial hypertension 30.6 TNF IL1B CXCL10
20 bacterial infectious disease 30.6 TNF IL6 IL1B IL10 IFNG CD40LG
21 lymphopenia 30.5 IL6 IL2 IL10 IFNG
22 polyneuropathy 30.5 TNF IL6 IL1B CD40LG
23 dengue hemorrhagic fever 30.5 TNF IL6 IL10 IFNG CD40LG
24 myelitis 30.5 TNF IL6 IL10 CD40LG
25 hemophagocytic lymphohistiocytosis 30.5 TNF IL10 IFNG
26 vaccinia 30.5 TNF IL6 IL2 ICAM1
27 exanthem 30.5 TNF IL6 IL2 IL1B IL10 IFNG
28 dengue disease 30.5 VCAM1 TNF ICAM1 CD40LG
29 crescentic glomerulonephritis 30.4 VCAM1 SELE ICAM1
30 ascaris lumbricoides infection 30.4 IL6 IL1B IL10 IFNG
31 acute myocarditis 30.3 TNF IL1B IL10 CD40
32 urticaria 30.3 TNF SELE IL6 IL10 CD40LG
33 arteriovenous malformation 30.3 TNF IL6 IL1B ANGPT2
34 diphtheria 30.3 TNF IL2 IL1B IFNG CD40LG
35 hemolytic anemia 30.3 TNF THBD IL2 IL10 IFNG G6PD
36 echinococcosis 30.2 TNF IL6 IL10 IFNG CD40LG
37 chickenpox 30.2 TNF IL6 IL2 IL10 IFNG CD40LG
38 anxiety 30.1 TNF IL6 IL1B CYP2D6
39 plasmodium falciparum malaria 30.1 TNF SELE IL6 IL10 IFNG ICAM1
40 neuritis 30.1 TNF IL6 IL1B IL10 IFNG CXCL10
41 purpura 30.1 TNF THBD IL6 IL10 IFNG CD40LG
42 brucellosis 29.9 TNF IL6 IL2 IL10 IFNG CD40LG
43 optic neuritis 29.9 VCAM1 TNF IL6 IL1B IL10 CXCL10
44 neutropenia 29.9 TNF IL6 IL2 IL1B IL10 IFNG
45 appendicitis 29.9 TNF IL6 IL2 IL1B IL10 IFNG
46 typhoid fever 29.7 TNF THBD IL6 IL1B IFNG CD40LG
47 chronic kidney disease 29.7 VCAM1 TNF THBD IL6 IL1B IL10
48 peripheral nervous system disease 29.6 TNF IL6 IL2 IL1B IL10 IFNG
49 bronchiolitis 29.6 TNF IL6 IL4R IL10 IFNG CXCL10
50 adult respiratory distress syndrome 29.5 TNF THBD SELE IL6 IL1B IL10

Graphical network of the top 20 diseases related to Plasmodium Vivax Malaria:



Diseases related to Plasmodium Vivax Malaria

Symptoms & Phenotypes for Plasmodium Vivax Malaria

GenomeRNAi Phenotypes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CD40LG IL10 IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ICAM1 IL10 IL1B IL2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 DHFR ICAM1

MGI Mouse Phenotypes related to Plasmodium Vivax Malaria:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.4 ANGPT2 CD40LG CXCL10 DHFR G6PD ICAM1
2 cellular MP:0005384 10.39 ANGPT2 CD40LG CXCL10 DHFR G6PD ICAM1
3 homeostasis/metabolism MP:0005376 10.39 ACKR1 ANGPT2 CD40 CD40LG CXCL10 DHFR
4 hematopoietic system MP:0005397 10.36 CD40 CD40LG CXCL10 DHFR G6PD ICAM1
5 immune system MP:0005387 10.33 ACKR1 ANGPT2 CD40 CD40LG CXCL10 DHFR
6 growth/size/body region MP:0005378 10.29 DHFR G6PD ICAM1 IFNG IL10 IL1B
7 mortality/aging MP:0010768 10.16 ANGPT2 CD40LG CXCL10 DHFR G6PD ICAM1
8 digestive/alimentary MP:0005381 10.15 ANGPT2 ICAM1 IFNG IL10 IL2 IL4R
9 integument MP:0010771 10.15 ANGPT2 CD40LG DHFR ICAM1 IFNG IL10
10 liver/biliary system MP:0005370 9.97 DHFR IFNG IL10 IL2 IL4R IL6
11 nervous system MP:0003631 9.73 CD40 CD40LG CXCL10 G6PD ICAM1 IFNG
12 neoplasm MP:0002006 9.7 ICAM1 IFNG IL10 IL1B IL2 IL6
13 respiratory system MP:0005388 9.28 ANGPT2 IFNG IL10 IL2 IL4R IL6

Drugs & Therapeutics for Plasmodium Vivax Malaria

Drugs for Plasmodium Vivax Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sulfadoxine Approved, Investigational Phase 4 2447-57-6 17134
2
Pyrimethamine Approved, Investigational, Vet_approved Phase 4 58-14-0 4993
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Lumefantrine Approved Phase 4 82186-77-4 6437380
5
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
6
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
7
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
8
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
9
Primaquine Approved Phase 4 90-34-6 4908
10
Piperaquine Experimental, Investigational Phase 4 4085-31-8 5079497
11
Dihydroartemisinin Experimental, Investigational Phase 4 71939-50-9 6918483
12 Artemether, Lumefantrine Drug Combination Phase 4
13 Anthelmintics Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Antiviral Agents Phase 4
16 Artemisinine Phase 4
17 Analgesics Phase 4
18 Artemisinins Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21
Amodiaquine Approved, Investigational Phase 3 86-42-0 2165
22 Orange Approved Phase 3
23
leucovorin Approved Phase 3 58-05-9 6006 143
24
Dapsone Approved, Investigational Phase 3 80-08-0 2955
25
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
26
Chlorproguanil Investigational Phase 3 537-21-3 151170 9571037
27
Imidacloprid Vet_approved Phase 3 105827-78-9 86418
28
Pyronaridine Investigational Phase 3 74847-35-1 5485198
29 Anti-Bacterial Agents Phase 3
30 Vitamin B Complex Phase 3
31 Fanasil, pyrimethamine drug combination Phase 3
32 Folic Acid Antagonists Phase 3
33 Folate Phase 3
34 Vitamin B9 Phase 3
35
Tinidazole Approved, Investigational Phase 2 19387-91-8 5479
36
tafenoquine Approved, Investigational Phase 2 106635-80-7 115358
37 Alkylating Agents Phase 2
38 Immunologic Factors Phase 2
39 Immunoglobulins Phase 1, Phase 2
40 Antibodies Phase 1, Phase 2
41 Vaccines Phase 1, Phase 2
42
Mannitol Approved, Investigational Phase 1 69-65-8 6251 453
43
Moxifloxacin Approved, Investigational Phase 1 354812-41-2, 151096-09-2 152946
44
Ritonavir Approved, Investigational Phase 1 155213-67-5 392622
45
Metoprolol Approved, Investigational Phase 1 37350-58-6, 51384-51-1 4171
46 Pharmaceutical Solutions Phase 1
47 Adjuvants, Immunologic Phase 1
48 diuretics Phase 1
49 Freund's Adjuvant Phase 1
50 Norgestimate, ethinyl estradiol drug combination Phase 1

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
2 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
3 A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam Completed NCT01887821 Phase 4 Chloroquine;Dihydroartemisinin/Piperaquine
4 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Completed NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
5 Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area Completed NCT02118090 Phase 4 Chloroquine sulfate;DHA-PP
6 Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection Completed NCT01680406 Phase 4 Artemether-lumefantrine combination;Primaquine;Chloroquine
7 A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan Completed NCT02592408 Phase 4 ASP;SDPQ;14DPQ;14DPQ on Day 42
8 A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh Completed NCT02389374 Phase 4 chloroquine;Artemether-lumefantrine combination;Primaquine;Primaquine
9 An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species Completed NCT00935688 Phase 4
10 Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
11 Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico Completed NCT02394197 Phase 4 Chloroquine phosphate;primaquine
12 G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria Recruiting NCT02876549 Phase 4 Chloroquine;Primaquine 0.25 mg/kg/day;Primaquine 0.75 mg/kg weekly
13 Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial Recruiting NCT03916003 Phase 4 primaquine
14 Short Course Radical Cure of P.Vivax in Nepal Not yet recruiting NCT04079621 Phase 4 primaquine
15 A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil Terminated NCT01107145 Phase 4 Mefloquine- Artesunate;Artemether-Lumefantrine;Chloroquine
16 Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations Terminated NCT03337152 Phase 4 primaquine;chloroquine + primaquine
17 Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine. Withdrawn NCT00290420 Phase 4 Chloroquine profilaxis
18 Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia Unknown status NCT02348788 Phase 3 Artemether-lumefantrine + Primaquine;Chloroquine + Primaquine
19 Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan Completed NCT01625871 Phase 3 tablets artemether/lumefantrine
20 A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria Completed NCT00440999 Phase 3 Pyronaridine artesunate;Chloroquine
21 Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax Completed NCT01640574 Phase 3 Dihydroartemisinin-Piperaquine;Dihydroartemisinin-Piperaquine;Chloroquine;Chloroquine
22 Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup Completed NCT01288820 Phase 3 Dihydroartemisinin/piperaquine + primaquine;Artesunate-amodiaquine + primaquine
23 Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria Completed NCT02802501 Phase 3 Tafenoquine;Matched-Placebo for Tafenoquine;Primaquine;Matched-Placebo for Primaquine;Dihydroartemisinin-piperaquine (DHA-PQP);ACT plus PQ (Rescue medication);PQ (End of study treatment)
24 A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria Completed NCT02216123 Phase 3 Tafenoquine;Tafenoquine Placebo;Chloroquine;Primaquine;Primaquine Placebo
25 A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border Completed NCT01074905 Phase 3 Artesunate;Chloroquine;Chloroquine/Primaquine
26 Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan Completed NCT00682578 Phase 3 Dihydroartemisinin + Piperaquine (Artekin);artesunate-sulphadoxin/pyrimethamine, chloroquine
27 An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan Completed NCT00158561 Phase 3 sulfadoxine-pyrimethamine and chlorproguanil-dapsone
28 A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria. Completed NCT00158587 Phase 3 primaquine
29 Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan Completed NCT00158548 Phase 3 SP, chloroquine, amodiaquine, primaquine, artesunate
30 Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection Completed NCT02691910 Phase 2, Phase 3 Chloroquine;Primaquine
31 Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia Completed NCT01708876 Phase 3 Artesunate-mefloquine;Chloroquine;Primaquine
32 Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon Completed NCT01845701 Phase 3 Artesunate-Amodiaquine;Dihydroartemisinine-Piperaquine;Artemether-lumefantrine combination
33 An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria Recruiting NCT03208907 Phase 3 CQ coadministered with PQ;DHA-PQP coadministered with PQ;CQ and PQ starting on Day 42;DHA-PQP and PQ starting on Day 42
34 Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine - a Randomized Controlled Trial in P. Vivax Patients Not yet recruiting NCT04411836 Phase 3 Tafenoquine;Primaquine
35 A Phase III Randomised, Double-blind, Double-dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients in Korea With Acute Plasmodium Vivax Malaria Terminated NCT04368910 Phase 3 Pyronaridine - artesunate;Chloroquine
36 An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria Completed NCT02563496 Phase 2 Tafenoquine;Chloroquine
37 Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection Completed NCT01213966 Phase 2 OZ439
38 Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax Completed NCT00811096 Phase 2 Tinidazole;chloroquine
39 A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. Completed NCT01376167 Phase 2 Chloroquine 600mg;Chloroquine 300mg;Tafenoquine 50mg;Tafenoquine 100mg;Tafenoquine 300mg;Tafenoquine 600mg;Primaquine 15mg;Chloroquine 600mg (Part 2 );Chloroquine 300mg (Part 2 );Tafenoquine 300mg (Part 2);Primaquine 15mg (Part2 )
40 A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan. Completed NCT00486694 Phase 2 Sulfadoxine-pyrimethamine + artesunate;Chloroquine
41 A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01753323 Phase 2 KAF156
42 A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection Completed NCT01524341 Phase 2 KAE609
43 A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period Completed NCT02123290 Phase 2 DSM265 400mg;DSM265 xmg;DSM265 ymg
44 Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults Completed NCT01157897 Phase 1, Phase 2
45 Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites. Completed NCT01585077 Phase 1, Phase 2
46 Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax Completed NCT02083068 Phase 2
47 Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites Completed NCT01082341 Phase 1, Phase 2
48 A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 in Healthy Adults Living in the UK Recruiting NCT04201431 Phase 1, Phase 2
49 A Phase IIa Challenge Study to Assess Efficacy of the Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP and MVA PvDBP in Healthy Adults Living in the UK Recruiting NCT04009096 Phase 2
50 Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients Recruiting NCT03529396 Phase 2 Chloroquine;Primaquine;Primaquine;Chloroquine;Primaquine

Search NIH Clinical Center for Plasmodium Vivax Malaria

Inferred drug relations via UMLS 71 / NDF-RT 50 :


halofantrine
Halofantrine hydrochloride
Mefloquine
Mefloquine Hydrochloride
Primaquine
Primaquine Phosphate

Cochrane evidence based reviews: malaria, vivax

Genetic Tests for Plasmodium Vivax Malaria

Anatomical Context for Plasmodium Vivax Malaria

MalaCards organs/tissues related to Plasmodium Vivax Malaria:

40
Testes, T Cells, Neutrophil, Liver, Spleen, Bone, Kidney

Publications for Plasmodium Vivax Malaria

Articles related to Plasmodium Vivax Malaria:

(show top 50) (show all 1102)
# Title Authors PMID Year
1
FY polymorphisms and vivax malaria in inhabitants of Amazonas State, Brazil. 61 54
20162434 2010
2
[Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day]. 54 61
15330059 2004
3
Pharmacokinetics of primaquine in G6PD deficient and G6PD normal patients with vivax malaria. 61 54
8036681 1994
4
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia. 61
32511702 2020
5
Efficacy and Safety of Pyronaridine-Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar. 61
32524960 2020
6
Morphological and Transcriptional Changes in Human Bone Marrow During Natural Plasmodium vivax Malaria Infections. 61
32556188 2020
7
Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria. 61
32433338 2020
8
piggyBac-mediated germline transformation of the malaria mosquito Anopheles sinensis (Diptera: Culicidae). 61
32519503 2020
9
A Multistage Formulation Based on Full-Length CSP and AMA-1 Ectodomain of Plasmodium vivax Induces High Antibody Titers and T-cells and Partially Protects Mice Challenged with a Transgenic Plasmodium berghei Parasite. 61
32560380 2020
10
Case Report: Primaquine Failure for Radical Cure of Plasmodium vivax Malaria in Gambella, Ethiopia. 61
32394882 2020
11
Cytokine signatures of Plasmodium vivax infection during pregnancy and delivery outcomes. 61
32365058 2020
12
Population pharmacokinetics and pharmacodynamics of chloroquine in a Plasmodium vivax volunteer infection study. 61
32415986 2020
13
[Plasmodium vivax-malaria et år efter hjemkomst fra Indien]. 61
32400370 2020
14
Guaroa Virus and Plasmodium vivax Co-Infections, Peruvian Amazon. 61
32186493 2020
15
Modelling the epidemiology of residual Plasmodium vivax malaria in a heterogeneous host population: A case study in the Amazon Basin. 61
32168349 2020
16
Plasmodium vivax Malaria Viewed through the Lens of an Eradicated European Strain. 61
31697387 2020
17
New laboratory perspectives for evaluation of vivax malaria infected patients: a useful tool for infection monitoring. 61
32335079 2020
18
ASSESSMENT OF THE EFFICACY AND SAFETY OF CHLOROQUINE MONOTHERAPY FOR THE TREATMENT OF ACUTE UNCOMPLICATED GESTATIONAL MALARIA CAUSED BY P. VIVAX, CÓRDOBA, COLOMBIA, 2015-2017. 61
32418373 2020
19
Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis. 61
32036012 2020
20
A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria. 61
32053607 2020
21
An Activation-Clearance Model for Plasmodium vivax Malaria. 61
32052192 2020
22
Relapse or reinfection: Classification of malaria infection using transition likelihoods. 61
32022247 2020
23
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of Plasmodium vivax malaria. 61
31524099 2020
24
Effects of IgG and IgM autoantibodies on non-infected erythrocytes is related to ABO blood group in Plasmodium vivax malaria and is associated with anemia. 61
32097712 2020
25
Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency. 61
31770431 2020
26
A mathematical model for assessing the effectiveness of controlling relapse in Plasmodium vivax malaria endemic in the Republic of Korea. 61
31978085 2020
27
Evaluation of the CareStart™ glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in the field settings and assessment of perceived risk from primaquine at the community level in Cambodia. 61
32004348 2020
28
The immunology of Plasmodium vivax malaria. 61
31642531 2020
29
Clinical and epidemiological characterization of severe Plasmodium vivax malaria in Gujarat, India. 61
32490754 2020
30
A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation. 61
31925313 2020
31
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. 61
31900172 2020
32
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. 61
31811128 2019
33
Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. 61
31819291 2019
34
Killing of Plasmodium vivax by Primaquine and Tafenoquine. 61
31522991 2019
35
Malaria risk map for India based on climate, ecology and geographical modelling. 61
31724378 2019
36
Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. 61
31419296 2019
37
Multiple Splenic Infarcts Complicating Plasmodium vivax Malaria. 61
31593054 2019
38
Plasmodium vivax Malaria Presenting with Acute Systemic Capillary Leak Syndrome. 61
31571465 2019
39
Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: A prospective open-label efficacy trial. 61
31604130 2019
40
Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency. 61
31549159 2019
41
Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. 61
31549155 2019
42
Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. 61
31590661 2019
43
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. 61
31584960 2019
44
Apical membrane protein 1-specific antibody profile and temporal changes in peripheral blood B-cell populations in Plasmodium vivax malaria. 61
31271660 2019
45
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. 61
31327563 2019
46
Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. 61
31541097 2019
47
Imported Plasmodium vivax malaria complicated by reversible myocarditis. 61
31572056 2019
48
Singultus as an Unusual Debut of Plasmodium vivax Malaria. 61
31695971 2019
49
Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine. 61
31547827 2019
50
Comparison of malaria incidence rates and socioeconomic-environmental factors between the states of Acre and Rondônia: a spatio-temporal modelling study. 61
31484519 2019

Variations for Plasmodium Vivax Malaria

Expression for Plasmodium Vivax Malaria

Search GEO for disease gene expression data for Plasmodium Vivax Malaria.

Pathways for Plasmodium Vivax Malaria

Pathways related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 VCAM1 TNF IL6 IL4R IL2 IL1B
2
Show member pathways
13.91 TNF IL6 IL4R IL2 IL1B IL10
3
Show member pathways
13.78 TNF IL6 IL4R IL2 IL1B IL10
4
Show member pathways
13.62 TNF IL6 IL4R IL2 IL1B IL10
5
Show member pathways
13.52 TNF IL6 IL4R IL2 IL1B IL10
6
Show member pathways
13.4 VCAM1 TNF IL6 IL4R IL2 IL1B
7
Show member pathways
13.36 TNF IL6 IL4R IL2 IL1B IL10
8
Show member pathways
13.18 TNF IL6 IL2 IL1B IL10 IFNG
9
Show member pathways
12.93 TNF IL6 IL2 IL1B IL10 IFNG
10
Show member pathways
12.9 TNF IL6 IL2 IL1B IFNG ICAM1
11
Show member pathways
12.82 TNF IL6 IL2 IL1B CD40LG CD40
12
Show member pathways
12.76 TNF IL4R IL2 IL10 IFNG CD40LG
13
Show member pathways
12.74 TNF IL1B IFNG CD40LG CD40
14
Show member pathways
12.72 TNF IL6 IL2 IL1B IL10 IFNG
15
Show member pathways
12.71 TNF IL6 IL4R IL2 IL1B IL10
16
Show member pathways
12.69 TNF IL6 IL2 IL1B IL10 IFNG
17 12.66 VCAM1 TNF IL2 IL1B IL10 IFNG
18
Show member pathways
12.53 IL6 IL4R IL2 IL10 IFNG
19
Show member pathways
12.47 TNF IL6 IL2 IL10 CXCL10 ACKR1
20 12.46 TNF IL6 IL2 ICAM1 CD40
21
Show member pathways
12.45 TNF IL6 IL1B IFNG CXCL10
22
Show member pathways
12.45 TNF IL6 IL2 IL1B IFNG ICAM1
23
Show member pathways
12.39 TNF IL6 IL2 IL1B IL10 IFNG
24
Show member pathways
12.39 TNF IL1B IL10 IFNG CD40LG CD40
25 12.36 TNF IL6 IL1B IL10 IFNG
26
Show member pathways
12.35 TNF IL6 IL2 IL1B IL10
27
Show member pathways
12.32 TNF IL6 IL1B IFNG CXCL10
28 12.27 VCAM1 SELE ICAM1 CD40LG CD40
29 12.26 TNF IL6 IL1B IL10
30 12.18 VCAM1 TNF THBD SELE IL1B IFNG
31 12.17 VCAM1 ICAM1 CD40LG CD40
32 12.16 TNF IL6 IL2 IL1B IL10
33 12.14 TNF IL6 IL2 IL10 IFNG
34 12.1 TNF IL6 IL2 IL1B IFNG ICAM1
35 12.07 TNF IL6 IL1B IL10 IFNG
36
Show member pathways
12.07 TNF IL6 IL2 IL1B IL10 IFNG
37 12.06 VCAM1 TNF IL6 IL4R IL1B IL10
38 12.05 VCAM1 TNF IL1B ICAM1 CD40LG CD40
39 12.03 VCAM1 TNF SELE IL6 IL1B ICAM1
40 12.02 TNF IL6 IL4R IL1B
41 12.01 TNF IL6 IL1B IFNG ICAM1
42
Show member pathways
11.99 IL6 IL4R IL1B IFNG
43 11.93 SELE IL6 IL2 IFNG ICAM1
44 11.91 TNF IL2 IL1B IL10 IFNG
45 11.91 VCAM1 TNF THBD SELE IL6 IL1B
46 11.9 TNF IL6 IL1B IL10
47
Show member pathways
11.9 TNF IL2 IFNG CD40LG
48
Show member pathways
11.85 TNF CD40LG CD40
49
Show member pathways
11.79 TNF CD40LG CD40
50 11.73 TNF IL6 IL1B

GO Terms for Plasmodium Vivax Malaria

Cellular components related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TNF IL6 IL4R IL2 IL1B IL10
2 integral component of plasma membrane GO:0005887 9.86 VCAM1 TNF THBD SELE IL4R ICAM1
3 cell surface GO:0009986 9.8 VCAM1 TNF THBD ICAM1 CD40LG CD40
4 external side of plasma membrane GO:0009897 9.5 VCAM1 TNF THBD ICAM1 CXCL10 CD40LG
5 extracellular space GO:0005615 9.5 VCAM1 TNF THBD SELE IL6 IL4R

Biological processes related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TNF IL6 IL2 IL1B IL10 CXCL10
2 regulation of immune response GO:0050776 10.02 VCAM1 ICAM1 CD40LG CD40
3 defense response to virus GO:0051607 10 IL6 IFNG CXCL10 CD40
4 positive regulation of protein phosphorylation GO:0001934 9.98 TNF IL2 IL1B IFNG CD40
5 leukocyte migration GO:0050900 9.95 TNF THBD SELE IL1B ICAM1 ANGPT2
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.94 TNF IL6 IL1B IL10
7 response to lipopolysaccharide GO:0032496 9.93 THBD SELE IL1B IL10 ICAM1 CXCL10
8 positive regulation of inflammatory response GO:0050729 9.91 TNF IL2 IL1B IFNG
9 B cell differentiation GO:0030183 9.9 VCAM1 IL10 CD40LG
10 interferon-gamma-mediated signaling pathway GO:0060333 9.89 VCAM1 IFNG ICAM1
11 regulation of insulin secretion GO:0050796 9.89 TNF IL1B IFNG
12 response to glucocorticoid GO:0051384 9.89 TNF IL6 IL10
13 humoral immune response GO:0006959 9.88 TNF IL6 IFNG
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF IL6 IL1B ICAM1 CD40LG CD40
15 positive regulation of interleukin-6 production GO:0032755 9.87 TNF IL6 IL1B
16 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.87 TNF IL10 DDX39B
17 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.86 VCAM1 SELE ICAM1
18 inflammatory response GO:0006954 9.86 TNF SELE IL6 IL1B CXCL10 CD40LG
19 positive regulation of phagocytosis GO:0050766 9.85 TNF IL1B IFNG
20 positive regulation of interferon-gamma production GO:0032729 9.85 TNF IL2 IL1B
21 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF IL1B IFNG
22 protein kinase B signaling GO:0043491 9.84 TNF IL1B CD40
23 B cell proliferation GO:0042100 9.83 IL10 CD40LG CD40
24 positive regulation of cytokine secretion GO:0050715 9.83 TNF IL10 IFNG
25 positive regulation of nitric oxide biosynthetic process GO:0045429 9.83 TNF IL1B IFNG ICAM1
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL6 IL2 IFNG CD40
27 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL10
28 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
29 leukocyte cell-cell adhesion GO:0007159 9.81 VCAM1 SELE ICAM1 CD40LG
30 defense response to protozoan GO:0042832 9.8 IL4R IL10 CD40
31 positive regulation of interleukin-12 production GO:0032735 9.79 IFNG CD40LG CD40
32 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
33 leukocyte tethering or rolling GO:0050901 9.77 VCAM1 TNF SELE
34 astrocyte activation GO:0048143 9.77 TNF IL1B IFNG
35 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.75 TNF IL1B IFNG
36 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 TNF IL1B IL10
37 negative regulation of amyloid-beta clearance GO:1900222 9.73 TNF IFNG
38 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL2 CD40
39 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.73 TNF IL6 ICAM1
40 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 IL10 IFNG
41 negative regulation of lipid storage GO:0010888 9.72 TNF IL6
42 positive regulation of chemokine biosynthetic process GO:0045080 9.72 TNF IL1B IFNG
43 positive regulation of T cell proliferation GO:0042102 9.72 VCAM1 IL6 IL2 IL1B CD40LG
44 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IFNG
45 regulation of establishment of endothelial barrier GO:1903140 9.71 TNF IL1B
46 endothelial cell apoptotic process GO:0072577 9.71 TNF IL10
47 positive regulation of neuroinflammatory response GO:0150078 9.71 TNF IL6 IL1B
48 CD40 signaling pathway GO:0023035 9.7 CD40LG CD40
49 cellular response to lipopolysaccharide GO:0071222 9.7 TNF IL6 IL1B IL10 ICAM1 CXCL10
50 negative regulation of cytokine production involved in immune response GO:0002719 9.69 TNF IL10

Molecular functions related to Plasmodium Vivax Malaria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integrin binding GO:0005178 9.26 VCAM1 IL1B ICAM1 CD40LG
2 cytokine activity GO:0005125 9.23 TNF IL6 IL2 IL1B IL10 IFNG

Sources for Plasmodium Vivax Malaria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....